Products - Metabolic conditions | Topic | NICE

Showing 8 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over TS ID 10392
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
CAEL-101 with standard care for untreated amyloid light chain amyloidosis TS ID 10666
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Leriglitazone for treating X-linked andrenoleukodystrophy TS ID 9996
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy TSID 12015
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years ID6484
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years TSID 12046
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Govorestat for treating classic galactosemia in people 2 to 65 years TS ID 12071
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC